Skip to main content
Premium Trial:

Request an Annual Quote

Quark Kidney Transplant Drug Receives FDA Orphan Drug Status

Premium

Quark Pharmaceuticals announced this week that the US Food and Drug Administration has granted an orphan drug designation to the company's p53-targeting siRNA QPI-1002 as preventative of delayed graft function in kidney transplant patients.

The designation, Quark said, allows for possible research and development incentives, and qualifies the company for tax credits and a period of market exclusivity following market approval.

Quark said that it has completed dosing in the dose-escalation portion of a phase I/II trial of the drug, and that it has received a positive recommendation from an independent data safety monitoring board to progress the drug to the second portion of the study, which will evaluate the safety and potential clinical activity of QPI-1002.

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.